Publications
2 shownRole of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
Purpose To evaluate the effect of KRAS and epidermal growth factor receptor (EGFR) genotype on the response to erlotinib treatment in the BR.21, placebo-controlled trial. Patien...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 7,954
- Institution
- Ontario Institute for Cancer Research
External Links
Identifiers
- ORCID
- 0000-0002-9863-468X
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.